Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Integrated Diagnostics Holdings ( (GB:IDHC) ).
Integrated Diagnostics Holdings reported a significant 41% increase in revenue for the first nine months of 2025, totaling EGP 5.8 billion. This growth was driven by a 10% rise in tests performed and a 28% increase in average revenue per test. The company’s gross profit expanded by 60% to EGP 2.5 billion, and EBITDA grew by 63% to EGP 2.0 billion, reflecting strong operational efficiency and cost management. The acquisition of Cairo Ray for Radiotherapy further bolstered IDH’s radiology capabilities, aligning with its strategy to enhance its diagnostic platform. The expansion of IDH’s branch network by 105 new locations and the continued increase in test volumes underscore the company’s commitment to accessibility and market coverage. The company’s operations in Egypt, Jordan, and Nigeria showed robust growth, with Egypt contributing 84% of total revenue.
More about Integrated Diagnostics Holdings
Integrated Diagnostics Holdings (IDH) is a leading provider of diagnostic services operating in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan. The company focuses on delivering pathology and radiology services, aiming to create an integrated diagnostics platform across its regional markets.
Average Trading Volume: 197,677
Technical Sentiment Signal: Buy
Current Market Cap: $325.5M
For detailed information about IDHC stock, go to TipRanks’ Stock Analysis page.